Group 1 - The core viewpoint of the news is that 科笛-B (02487) experienced a significant stock price increase of over 14% despite reporting a substantial decline in revenue and an increase in net loss for the first half of the year [1] - The company's revenue decreased by 30.6% year-on-year to approximately 66.3 million HKD, while the net loss increased by about 19.1% to approximately 239 million HKD [1] - The decline in revenue is attributed to the company's decision to terminate its agency cooperation with the US skincare brand 欧玛 due to macroeconomic policies and international environment impacts, reallocating resources to new products with higher market potential [1] Group 2 - 科笛 plans to issue a total of 28.9 million placement shares at a price of 8.40 HKD per share, representing a discount of approximately 12.04% to the previous trading day's closing price of 9.55 HKD [2] - The net proceeds from the placement are expected to be approximately 240 million HKD, with 45% allocated for preclinical research and development, clinical trials, and production facility layout in areas such as localized fat management and skin diseases [2] - Another 45% of the proceeds will be used for marketing, channel expansion, and brand building for the new products CU-40102 and CU-10201, while the remaining 10% will be used for working capital and general corporate purposes [2]
港股异动 | 科笛-B(02487)早盘涨超14% 战略调整拖累上半年业绩 拟配股筹资加码研发及商业化